Thermo Fisher Scientific

Polymerase Chain Reaction (PCR) Technologies and Global Markets 2023-2028 - New Research Signals Robust Advancements and Expanding Applications in Molecular Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Friday, January 19, 2024
Health, Biotechnology, NGS, Research, Environmental science, Library, Agriculture, Danaher Corporation, Thermo Fisher Scientific, Molecular biology, Genetics, Laboratory, ESG, Real-time, Polymerase chain reaction, COVID-19, Medtech, USD, RT, PCR, Viral load, Nested polymerase chain reaction, Gene expression

The "Polymerase Chain Reaction (PCR) Technologies and Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polymerase Chain Reaction (PCR) Technologies and Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • From diagnostics, research, and agriculture to forensics and environmental science, PCR techniques are an essential element in the arsenal of today's scientists.
  • Although the fundamental concept of PCR has remained unchanged over the years, novel PCR methods/protocols have continued to advance.
  • With the recent inclination toward genomic and biomarker research and development, demands for advanced PCR technologies to study nucleic acid samples in greater detail have increased significantly.

Thermo Fisher Scientific Receives GMP approval from the Italian Medicines Agency (AIFA) for its Manufacturing facility of RNA-Based Products in Monza, Italy

Retrieved on: 
Friday, January 19, 2024
Biotechnology, Manufacturing, Other Health, Health, Pharmaceutical, Oncology, Research, Other Manufacturing, Infectious Diseases, Science, Clinical Trials, Patient, Syringe, RNA, Thermo Fisher Scientific, Good manufacturing practice, Cancer, Monza, GMP, Therapy, Vaccine, LNP

Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site.
  • The approval and associated certification support increased accessibility to novel therapies for patients with difficult to treat conditions, marking a significant achievement within the Thermo Fisher Scientific network and for Italy as a whole.
  • “RNA technology is being explored for a variety of modalities, including rare diseases and cancer which have limited treatment options,” said Dan Herring, General Manager, Advanced Therapies, Pharma Services at Thermo Fisher Scientific.
  • With more than 30 years of experience manufacturing sterile injectables, biologics, and advanced therapies, Thermo Fisher has the capabilities and expertise required to help customers accelerate development and increase access to therapies for patients globally.

iXCells Biotechnologies Strengthens Leadership Team; Welcomes New CEO

Retrieved on: 
Thursday, January 18, 2024
Research, Infectious Diseases, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Columbia Business School, Patient, University, Molecular diagnostics, IPSC, Biophysical chemistry, Sigma-Aldrich, SGS, Thermo Fisher Scientific, B cell, Business development, Executive, Disease, Drug development, QIAGEN, University of Göttingen, Doctor of Philosophy, Genome, Synthetic biology, Alumni, RUO, Nobel Prize, Growth, Management

To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.

Key Points: 
  • To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team.
  • Helge brings to iXCells a wealth of entrepreneurial and intrapreneurial leadership experience across the life sciences and healthcare space in building businesses for small and large companies with a proven track record of value creation.
  • In addition, Dr. Bastian led oncology focused Indivumed and M2GEN (now Aster Insights) as Managing Director & Chief Commercial Officer and CEO, respectively.
  • Dr. Lynn Zhang will continue to serve on iXCells’ board of directors and assist with transitioning CEO leadership responsibilities in the coming months.

Thermo Fisher Scientific Unveils Industry’s First Off-the-Shelf Validated Software Solution to Automate Cell Therapy Manufacturing Workflows

Retrieved on: 
Wednesday, January 17, 2024
Other Manufacturing, Technology, Manufacturing, Software, Biotechnology, Health, Pharmaceutical, Other Science, Science, Patient, CTS, Multimedia, Failure, CGMP, Thermo Fisher Scientific, DCS, Workflow, GMP, CFR, Distributed control system, Medical device

To optimize clinical manufacturing processes for innovators developing breakthrough cell therapies, Thermo Fisher Scientific today announced the launch of the Gibco™ Cell Therapy Systems (CTS™) Cellmation™ Software , a first-of-its-kind automation solution designed to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance.

Key Points: 
  • To optimize clinical manufacturing processes for innovators developing breakthrough cell therapies, Thermo Fisher Scientific today announced the launch of the Gibco™ Cell Therapy Systems (CTS™) Cellmation™ Software , a first-of-its-kind automation solution designed to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance.
  • View the full release here: https://www.businesswire.com/news/home/20240117931916/en/
    Gibco Cell Therapy Systems (CTS) Cellmation Software digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to streamline and automate manufacturing.
  • By establishing an automated workflow across multiple stages of cell therapy manufacturing, CTS Cellmation Software helps enable traceability, repeatability and 21 CFR Part 11 compliance with secured data connectivity.
  • At present, CTS Cellmation Software connects core Thermo Fisher Scientific cell therapy instruments, including solutions from our Gibco CTS portfolio.

Europe EV-Based Liquid Biopsy Market Analysis and Forecasts 2023-2032 Featuring Key Players - Abcam, Qiagen, Malvern Panalytical, and Lonza Group - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 17, 2024
Biotechnology, Health, Oncology, Neoplasm, EVS, Research, Liquid biopsy, Thermo Fisher Scientific, Cancer, Disease, EV, QIAGEN, Benchmarking, Lung, Prostate, Diagnosis, Growth, Medical imaging

The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease.

Key Points: 
  • The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease.
  • Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers.
  • Further, the amplified funding and dedicated research efforts in EV-based liquid biopsy market is a major driver of market growth.
  • What are the major market drivers, challenges, and opportunities and their respective impacts in the Europe EV-based liquid biopsy market?

The Europe Laboratory Information Management System (LIMS) Market to Reach $912.47 Million by 2028 - Exclusive Focus Insight Report by Arizton

Retrieved on: 
Thursday, January 25, 2024
Thermo Fisher Scientific, Research, Health, Abbott Informatics, Investment, Genomics, Pressure, Safety, LabWare, Laboratory, LabVantage, LIMS, Marketing, STARLIMS, Automation, Fine chemical

Check Out Arizton's Latest Research on the US Laboratory Information Management System Market,

Key Points: 
  • Check Out Arizton's Latest Research on the US Laboratory Information Management System Market,
    The US laboratory information management system market was valued at $613.27 million in 2022 and is expected to reach $1 billion by 2028, growing at a CAGR of 9.56%.
  • To Know More About the US Laboratory Information Management System Market, Click: https://www.focusreports.store/request-sample/us-laboratory-information-...
    Key questions Answered in the Report:
    How big is the Europe laboratory information management system (LIMS) market?
  • Who are the key players in the Europe laboratory information management system (LIMS) market?
  • Which region dominates the Europe laboratory information management system (LIMS) market?

The Europe Laboratory Information Management System (LIMS) Market to Reach $912.47 Million by 2028 - Exclusive Focus Insight Report by Arizton

Retrieved on: 
Thursday, January 25, 2024
Thermo Fisher Scientific, Research, Health, Abbott Informatics, Investment, Genomics, Pressure, Safety, LabWare, Laboratory, LabVantage, LIMS, Marketing, STARLIMS, Automation, Fine chemical

Check Out Arizton's Latest Research on the US Laboratory Information Management System Market,

Key Points: 
  • Check Out Arizton's Latest Research on the US Laboratory Information Management System Market,
    The US laboratory information management system market was valued at $613.27 million in 2022 and is expected to reach $1 billion by 2028, growing at a CAGR of 9.56%.
  • To Know More About the US Laboratory Information Management System Market, Click: https://www.focusreports.store/request-sample/us-laboratory-information-...
    Key questions Answered in the Report:
    How big is the Europe laboratory information management system (LIMS) market?
  • Who are the key players in the Europe laboratory information management system (LIMS) market?
  • Which region dominates the Europe laboratory information management system (LIMS) market?

Electron Microscope Market size to grow by USD 1.68 billion from 2022 to 2027; APAC to account for 55% of market growth- Technavio

Retrieved on: 
Tuesday, January 16, 2024
TESCAN, Semiconductor, JEOL, Research, EDS, ROW, Geography, Sony, Carl Zeiss AG, LG, Transmission electron microscopy, Nanotechnology, Thermo Fisher Scientific, TEM, Scanning electron microscope, Growth, Samsung, Carbon, Investment, Biology, FEI Company, Image, USD, HREM, Virus, Keysight, Protein, Free, EBSD, Cryogenic electron microscopy, Toshiba, Energy, Microscope

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The electron microscope market is expected to grow by USD 1.68 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The electron microscope market is expected to grow by USD 1.68 billion from 2022 to 2027.
  • The transmission electron microscope market size is estimated to grow by USD 458.93 million at a CAGR of 10.32% between 2022 and 2027.
  • The global scanning electron microscope (SEMs) market size is estimated to grow by USD 997.21 million at a CAGR of 8.01% between 2022 and 2027.
  • Growth of the electron microscope market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of electron microscope market companies.

Pharmaceutical Contract Research and Manufacturing (CRAM) Market size to grow by USD 121.35 billion from 2022 to 2027; Asia to account for 41% of market growth - Technavio

Retrieved on: 
Tuesday, January 16, 2024
ChromeOS, Catalent, Recipharm, Parexel, ROW, Geography, Biotechnology, Syneos Health, Thermo Fisher Scientific, ICON PLC, ICON, CMO, CRAM, USD, Free, Lupin Limited, Research, IQVIA, Growth, Fine chemical

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of 10.32% during the forecast period, according to Technavio Research.
  • For additional data on Market Size (2017) Historic Year, Market Size - Forecasted Year, Historic Opportunity (2017-2021), Historic CAGR, Forecasted Opportunity (2023-2027), Market Opportunity Transformation Growth, and Market Opportunity Capitalization.
  • Pharmaceutical Contract Research And Manufacturing (CRAM) Market: Segmentation Analysis
    The market share growth of the CMO segment will be significant during the forecast period.

Chromatography Instrumentation Market Size to Hit USD 14 Billion by 2035 | Roots Analysis

Retrieved on: 
Monday, January 15, 2024
Research, UPLC, Biotechnology, Thermo Fisher Scientific, QC, Chromatography, Acquisition, Laboratory, Automation, Valmet, Particle size, Growth, Instrumentation

LONDON, Jan. 15, 2024 /PRNewswire/ -- The global chromatography instrumentation market is growing rapidly; it is estimated to be worth USD 7.6 billion in 2023 and is anticipated to reach USD 14 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 5.3% during the forecast period from 2023 to 2035.

Key Points: 
  • Secondly, the chromatography instrumentation market is also driven by the rapidly evolving purification process-specific requirements across different industries.
  • The high cost associated with the development of chromatography instrumentation and operational expenditures are the two major market restraints that impede the growth of the market.
  • The lack of skilled personnel to operate the instrument is considered a key market restraint that restricts the growth of the chromatography instrumentation market.
  • Request Free Sample PDF Copy at:
    Based on the type of chromatography instruments, the market is segmented into liquid chromatography, gas chromatography, and other systems.